Patent Application
App. No. 17/962,626
COMPOSITIONS COMPRISING EPHEDRINE OR AN EPHEDRINE SALT AND METHODS OF MAKING AND USING SAME
Loading inventors, assignments & file history…
Abstract
The present disclosure provides compositions comprising ephedrine sulfate ready for immediate use in a clinical setting, and methods of making and using same.
Claims (7)
1 . A storage-stable, sterile, ready-to-use ephedrine solution comprising:
5 mg/mL ephedrine sulfate;
9 mg/mL sodium chloride;
no preservative;
water;
an initial pH level of about 4.5 to about 7; and
a pH level within 0.5 pH units of the initial pH level after storage at 25° C. and 60% relative humidity for 12 months or after storage at 40° C. and 75% relative humidity for 6 months.
Assignments (5)
RELEASE OF SECURITY INTEREST
Recorded Jun 3, 2024
From: SAGENT GROUP, LLC
To: NEXUS PHARMACEUTICALS, LLC; NEXPHARM PARENT HOLDCO, LLC; ISOPRO HOLDINGS, LLC
Reel/Frame 067600/0837 →
CHANGE OF NAME
Recorded May 26, 2023
From: NEXUS PHARMACEUTICALS II, LLC
To: NEXUS PHARMACEUTICALS, LLC
Reel/Frame 063789/0675 →
STATUTORY CONVERSION
Recorded May 24, 2023
From: NEXUS PHARMACEUTICALS, INC.
To: NEXUS PHARMACEUTICALS II, LLC
Reel/Frame 063752/0975 →
SECURITY INTEREST
Recorded May 8, 2023
From: NEXUS PHARMACEUTICALS, LLC; NEXPHARM PARENT HOLDCO, LLC; ISOPRO HOLDINGS, LLC
To: SAGENT GROUP, LLC
Reel/Frame 063568/0369 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 10, 2022
From: AHMED, SHAHID
To: NEXUS PHARMACEUTICALS, INC.
Reel/Frame 061359/0539 →